We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 40

Teva Canada Innovation v. Attorney General of Canada

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 8 2013

The Patented Medicine Prices Review Board (the PMPRB) ordered Teva to pay the Crown approximately $2.4 million for selling its product at an

Federal Court sets aside PMPRB decision regarding COPAXONE syringes for the second time

  • Smart & Biggar/Fetherstonhaugh
  • -
  • Canada
  • -
  • May 7 2013

On April 30, 2013, Justice Zinn of the Federal Court set aside a decision of the PMPRB (the "Board"), which ordered (Order, Reasons) Teva to pay the

Northern exposure?

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, USA
  • -
  • April 4 2013

Davit Akman and John Norman suggest that a recently commenced investigation into alleged "product switching" and statements by the Interim

Supreme Court of Canada holds that PMPRB has jurisdiction over sales made ''into Canada'' pursuant to the special access program (Thalomid)

  • Norton Rose Canada LLP
  • -
  • Canada
  • -
  • January 20 2011

On January 20, 2011, the Supreme Court of Canada dismissed an appeal by Celgene Corporation ("Celgene") and held that the Patented Medicine Prices Review Board ("Board") has jurisdiction to regulate the price of patented medicines that are sold into Canada pursuant to the Health Canada Special Access Program as part of its "consumer protection" mandate

Competition Bureau reaches agreement in TevaRatiopharm merger

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • August 25 2010

On July 30, 2010, the Competition Bureau (Bureau) announced that it had reached a consent agreement with Teva Pharmaceuticals Industries Ltd. (Teva) and the Merckle Group, carrying on business as ratiopharm, requiring the divestiture of assets and associated licenses in relation to certain forms of acetaminophen oxycodone tablets and morphine sulfate sustained release tablets

BC pharmaceutical policy reforms

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 16 2010

Following the lead of Ontario, British Columbia has taken steps to further reform its provincial policy with respect to pharmaceuticals

Celgene Corporation v Canada (AG) - Supreme Court of Canada grants leave to appeal

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 21 2010

The Supreme Court of Canada has granted Celgene Corporation's application for leave to appeal the decision of a majority of the Federal Court of Appeal regarding the jurisdiction of the Patented Medicine Prices Review Board

An overview of Ontario’s proposed drug pricing regulatory reforms

  • McMillan LLP
  • -
  • Canada
  • -
  • April 26 2010

Recently announced changes to Ontario's drug pricing laws will potentially have a significant impact on the bottom line of many stakeholders in the Ontario generic drug industry

First PMPRB decision dismissing allegations of excessive pricing

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 20 2010

The Patented Medicine Prices Review Board ("PMPRB") recently released its decision in the matter of Hoechst Marion Roussel Canada Inc. and the medicine NIOCODERM, a nicotine patch which assists those who are attempting to quit smoking; it is to be publicly posted on the PMPRB website today

Implementation of changes to Competition Act - implications for biotech and pharma sector

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 15 2010

There are some important changes to the Competition Act (the "Act") that came into effect on March 12, 2010, that are of particular interest to the biopharmaceutical sector

Current Search

Suggested Facets

Author

Firm Name

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy